Inhibiting sortilin specifically prevents the transformation of VICs into myofibroblasts, potentially slowing or halting CAVD progression (Figure 4) [72]. This evidence concerns the gene SORT1 and congenital bilateral aplasia of vas deferens from CFTR mutation.